Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
BAUDETTE, Minn. - ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) saw its stock jump 12.4% after the specialty pharmaceutical company reported fourth quarter earnings that beat analyst expectations and raised its full-year 2025 guidance significantly above consensus estimates.
The company reported adjusted earnings per share of $1.63, surpassing the analyst estimate of $1.45. Revenue for the quarter came in at $190.6 million, exceeding the consensus estimate of $175.12 million and representing a 44.8% increase year-over-year.
ANI’s Rare Disease segment was a key driver of growth, with revenue more than doubling to $87 million. This included $59.4 million from Cortrophin Gel, up 42.3% YoY, and $27.6 million from newly acquired ophthalmology drugs ILUVIEN and YUTIQ.
"We’re thrilled to report another year of strong execution for ANI, capped by our record fourth quarter results," said Nikhil Lalwani, President and CEO of ANI.
Looking ahead, ANI raised its 2025 guidance, now expecting revenue between $756 million and $776 million, up from its previous forecast of $739 million to $759 million and above the analyst consensus of $724.9 million. The company also introduced adjusted EPS guidance of $6.12 to $6.49, well above the $5.56 analyst estimate.
ANI attributed its strong outlook to continued momentum in its Cortrophin Gel business and the integration of its new ophthalmology franchise. The company expects Rare Disease net revenues to represent 48% to 49% of total company revenues in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.